The Southern District of New York certified a class for the class action suit against New York State’s Human Resources Administration based on the reduction of 24-hour home care services for people already receiving the service. The class consists of, among others, current Medicaid recipients who are in the continuous 24-hour home care program and who have experienced threats of reduction or actual reduction of the home care service. The certified class claims the evaluation process for home care was used as “a policy and practice of arbitrarily and irrationally reducing or discontinuing Plaintiff’s…home care services.”
Adderall XR Shortage
Effected by the unavailability of generic Adderall XR due to the shortage?
Were you forced to purchase Adderall XR brand product because drug manufacturers failed to manufacturer generic versions of the drug?
Have you paid inflated prices for the Adderall XR brand product and deprived of the benefits from less expensive generic versions of the medicine?
Do you suffer from Attention Deficit Hyperactivity Disorder (“ADHD”)?
Have you been unable to fill your generic Adderall XR prescription due to its unavailability?
Are you considering an Adderall shortage lawsuit?
Shire LLC and Shire U.S., Inc. (“Shire”) are pharmaceutical drug manufacturers that are alleged to have unlawfully excluded, impeded and restrained competition for a certain generic mixture of amphetamine salts that are sold as Adderall XR, which are commonly used in treating ADHD. It is being claimed that Shire monopolized the market for Adderall XR by falsely promising to provide generic manufacturers with the active pharmaceutical ingredients of Adderall XR for purposes of inducing the settlement of patent litigation and enabling them to sell competing Adderall XR products, while continuing to receive a royalty on such sales.
As of late 2010, it has been published that Shire deliberately defaulted on such agreements for the anti-competitive purpose of impeding generic rivals so that users of the medication would be forced to purchase the Adderall XR brand product at inflated prices. Thereby keeping cheaper generic versions of Adderall XR out of the market, decreasing competition and resulting in drastic increased in the price of prescription Adderall XR. It has been reported that generic Adderall XR is in such short supply that users of the medication are unable to fill their prescriptions. Many believe that an Adderall shortage lawsuit is impending.
The Adderall XR Shortage attorneys of Bashian & Papantoniou are currently investigating whether Shire has violated the laws by eliminating generic versions of Adderall XR from the marketplace. For more information or a free case evaluation on the Adderall shortage lawsuit, please contact our Adderall XR Shortage attorneys of Bashian & Papantoniou, P.C., by mail at 500 Old Country Road, Suite 302, Garden City, New York 11530 or by telephone at (516) 279-1554, or by email at email@example.com, or visit our website at www.bashpaplaw.com
It appears a legal battle is waiting in the wings to determine the proper venue for the divorce suit between actors Katie Holmes and Tom Cruise, and custody over their daughter Suri. According to New York state law, a couple must satisfy one of the following residency requirements to be divorced in New York:
- You or your spouse must have been living in New York State for a continuous period of at least two years immediately before the date you start your divorce action; OR
- You or your spouse must have been living in New York State on the date you start your divorce action and for a continuous period of at least one year immediately before the date you start the divorce action, and at least one of the following must also be true:
- Your marriage ceremony was performed in New York State; OR
- You lived in New York State with your spouse as married persons; OR
- You or your spouse must have been living in New York State for a continuous period of at least one year immediately before the date you start your divorce action and your grounds for divorce must have happened in New York State. (“Grounds” means a legal reason for the divorce); OR
- You and your spouse must be residents of New York State (no matter how long) on the date you start your divorce action, and your grounds for divorce must have happened in New York State. (“Grounds” means a legal reason for the divorce).
Holmes is believed to have been renting an apartment in Manhattan just prior to her filing for divorce and also claims in her divorce papers that the former couple are residents of New York State.
The Massapequa High School Mock Trial Team edged past Roslyn High School to win the Marcus G. Christ Championship Trophy in the New York State High School Mock Trial Tournament (“NYSHSMTT”). The NYSHSMTT is the nation’s largest moot court competition for high schools and provides students with an opportunity to orally advocate their cases in the Nassau Supreme Court before New York judges and attorneys. The competition hosts45 high schools, 500 students and more than 120 attorneys and judges. New York trial attorney Erik M. Bashian credits the Nassau County Bar Association for doing a wonderful to coordinate the competition and create public awareness.
A loan is usurious and unenforceable if it seeks recovery of annualized interest rate in excess of 16 % from individual borrowers
The New York General Obligations Law provides that the legal rate of interest charged on a loan is six (6) percent per annum unless a different rate of interest is fixed under section 14 (a) of the Banking Law. Section 14 (a) of the New York Banking Law holds that the maximum rate of interest shall be sixteen (16) percent per year. Therefore, it is black letter law that a loan agreement that charges an individual borrower with interest in excess of 16% is usurious, on its face, and may be unenforceable. Please contact the New York trial attorneys at Bashian & Papantoniou for a consultation, if you have been sued under a loan agreement that seeks annualized interest at a rate in excess of 16%.
Lenders that seek to recover compound monthly interest on loans for less than $250,000 are unenforceable and void
New York statutory law limits a lender’s ability to collect compound interest on any loan for $250,000 or less. Indeed, “compound interest” is commonly defined as interest on interest or interest that is paid on both the principal and the previously accumulated interest. “Compound interest” contrasts with “simple interest,” which is “paid on the principal only and not on accumulated interest” in that simple interest does not merge with principal and thus does not become part of the base for the computation of future interest. A promise to pay “interest upon interest” is void if made at a time before simple interest has accrued. In 1989, the legislature enacted the relevant statute, as a mean of public policy to prevent creditors from silently permitting debts to progressively mount at the expense of debtors who, often unaware of the consequences of such agreement, tend to confuse forbearance with indulgence. Please contact the New York trial attorneys at Bashian & Papantoniou for a consultation, if you have been sued under a loan agreement that seeks monthly compound interest on a loan for less than $250,000.
The New York Supreme Court in Emery Celli Brinckerhoff & Adaby v. Rose, Index No. 103871/10, recently ruled that the “account stated rule” makes a client liable for the outstanding balance on a legal invoice. The court reasoned that when a client pays part of a bill, such client is generally deemed to have accepted the entire billing as valid. The court also noted that the invoices, which were challenged by the client detailed the outstanding bills and were not rebutted as to why or how they were excessive. In New York State, the Court
System has established a Statewide Fee Dispute Resolution Program (“FDRP”) to resolve attorney-client disputes over legal fees through arbitration and sometimes even mediation. Generally, an attorney may not sue a client in court over a fee dispute unless he or she first provided the client with notice of the right to utilize the FDRP. Once the client has received this notice, he or she has 30 days to decide whether to use the FDRP. If the client doesn’t choose to participate in the FDRP within 30 days, the attorney is free to pursue the matter in court. Read more to learn about your rights here: http://www.nycourts.gov/admin/feedispute/pdfs/FD_brochure.pdf and contact the attorneys at Bashian & Papantoniou, PC, to resolve your attorney fee disputes.
Erik Bashian, head of the Litigation Department of Bashian & Papantoniou, discusses the “lost” Green Jacket of ’59 Masters Champion Art Wall Jr. with The Star-Ledger
In 1959, Art Wall Jr. obtained his most notable career victory by winning the Masters Tournament and being awarded his first and only green jacket. A few years later, the Wall family claims the treasured green jacket that Wall wore as an Augusta champion disappeared from his family’s’ home and was not discovered until two weeks ago when it was put up for auction on a the golf memorabilia website http://www.greenjacketauctions.com.
Bashian, likened the facts of Wall’s lost jacket to those in the 1991 New York Court of Appeals case Solomon R. Guggenheim Foundation v. Lubell, where the court ruled that because many other difficulties exist for a rightful owner in locating and recovering artwork that may have been lost or stolen, such owner should not also have to bear the additional burden in demonstrating due diligence in tracking down the lost art. He added that, “with a potential good-faith purchaser lined up to make a substantial purchase, there should be absolute certainty on their part as to how the jacket was acquired initially.”
Under New York law, an action to recover damages for the unlawful taking of one’s property, such as sports memorabilia, must be commenced within three years, from the time the theft occurs.
However, a rightful owner’s replevin action for the return of such property against who may be an innocent purchaser does not accrue until the rightful owner demands the return of the stolen property from the possessor and such possessor refuses to return it. As a matter of substantive law, the good-faith purchaser has not done any wrong until he/she refuses a demand for the return. Although, in New York, an owner’s failure to exercise due diligence in locating a lost chattel has not been held to be a factor in determining the accrual of the statute of limitations, it may be relevant with respect to a trial court adjudicating the good faith purchaser’s equitable defense of laches. If you have a legal issue concerning sports memorabilia and would like to speak with one of the sports memorabilia attorneys at Bashian & Papantoniou, please contact us at (516) 279-1555 to schedule a consultation.
At Bashian & Papantoniou, our sports memorabilia attorneys in Long Island and New York provide invaluable advice and guidance to buyers, sellers and auctioneers on various legal issues that may arise in connection with a sports memorabilia transaction.
Read the Full Article Here
Nike successfully obtained a temporary restraining order barring Reebok from selling apparel with Tim Tebow’s name on it, following the Jets’ acquisition of Tebow in March. Nike is set to replace Reebok, a subsidiary of Adidas AG, as the official supplier of NFL uniforms on April 1. Reebok was the NFL’s supplier of on-field apparel, including game uniforms, and sideline apparel for the past decade, according to ESPN. Nike will be supplying that apparel exclusively for all thirty-two NFL teams for the next five years. Prior to March 1, 2012, Reebok has printed and sold Broncos jerseys with Tebow’s name and number, per Reebok’s contract with the NFL. However, Nike contends that at this time, Nike, to Reebok’s exclusion, possesses the license required to manufacture and sell jerseys related to Tebow after his move from the Broncos. Nike contends that Reebok was shipping large volumes of Tebow-related products to capitalize on his recent move to the Jets, harming Nike’s ability to capitalize on a “unique and short-lived opportunity,” according to Nike’s lawsuit and ESPN.
Federal District Judge Castel of the Southern District of New York in Manhattan agreed with Nike, ordering Reebok to stop producing and selling any Tim Tebow-related products that were manufactured after March 1, 2010, and all Tebow-related products that relate to any other team than the Broncos. However, in the published court order, Judge Castel stopped short of requiring that Reebok “destroy all unauthorized Tebow products that are now in, or hereafter come into, Reebok’s custody, possession, or control.” A preliminary injunction hearing will take place on April 4, 2012.
Even though many Americans assume that there is no difference between a brand-name drug and its generic equivalent, the legal remedies for victims of a drug’s side-effects of medication may depend in large part on the distinction. The Supreme Court, in deciding Pliva v. Mensing last summer, established protections for generic pharmaceutical companies for claims alleging failure to warn; such protections do not exist for brand-name manufacturers. The difference is with regard to who controls what is said on the drug’s label.
Under federal law, drug manufacturers may establish that the drug they produce is equivalent to a brand-name drug already on the market. In doing so, the a drug manufacturer establishes that its medication is a “generic” drug, and sidesteps a lengthy FDA approval process. One consequence of this process is that the generic drug manufacturer must adopt the label of the brand-name equivalent.
Since generic drug manufacturers do not have control over the label that is placed on the drugs they produce, the Supreme Court reasoned that those manufacturers do not have liability for inadequate labels. This means that when a patient is harmed by a side-effect of a drug, that patient can sue the drug manufacturer alleging a failure to warn of those side-effects only if the manufacturer has control over the label – this requirement exempts generic drug manufacturers from liability.
However, both the FDA and Congress have the power to restore a patient’s right to sue a generic drug manufacturer for failure to warn, by providing the generic drug manufacturer the responsibility to warn about side-effects without regard to the warning label provided on the brand-name equivalent. Until such a change, however, patients who take brand-name drugs have access to a broader range of legal remedies than do patients who take generics.